ClinicalTrials.gg
TerminatedNCT02711254PhantomUpdated Nov 18, 2026Results posted

Phantom Knee System Clinical Trial

An interventional study of Phantom System in Osteoarthritis of the Knee, sponsored by Moximed. Terminated at 4 sites in 2 countries. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Moximed · Not applicable, Interventional, and Treatment

Why this study was terminated
Adequate data has been collected

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Oct 2014, registered Jan 2016).
Updated Nov 18, 2026Now TerminatedResults posted+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 78 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.

Enrollment
69th of 72
40 · median 115
Started
2014
with 1 other
No phase
28 of 78
9 open now
Registered
10th of 78
by date
Lead sponsor
2 of 78
Moximed

Among the 78 studies in Osteoarthritis, Knee with a site in Poland, this one is the 69th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2014, is one of 28 with no phase, and was the 10th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 78 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Osteoarthritis, Knee with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate improvement in pain and function following implantation of a new device, called the Phantom Knee System, in patients needing unloading of the medial compartment of the knee

Read the detailed description

This is a prospective, multi-center, single-arm, first in human (FIH) study. Patients will be asked to participate in the study and follow up for a 24 month period following implantation of the study device.

03

Conditions studied

  • Osteoarthritis of the Knee
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 25 and 65 years of age, inclusive
  2. Documented pathology of the medial compartment of the knee that requires unloading with
  3. Tibial femoral varus alignment of ≤7⁰ as measured using mechanical axis on a long standing anterior-posterior (AP) view X-ray
  4. Has continued target knee pain despite 6 months of conservative treatment prior to surgery
  5. Has pain in the target knee as demonstrated by a minimum score of 40 (scale 0-100) on the KOOS pain domain questions
  6. Knee flexion ≥90⁰ to ≤140⁰
  7. 24-35 kg/m²
  8. Weight ≤ 110 kg
  9. Willing and able to give and have given voluntary written to participate in this clinical investigation
  10. Prepared to consent to the transfer of his/her information to third parties
  11. Willing to undertake the required procedures and willing to return for the required follow-up evaluations

Exclusion criteria

Exclusion Criteria:

  1. Active infection, sepsis, osteomyelitis or history of septic arthritis in any joint.
  2. Rheumatoid arthritis or other forms of inflammatory joint disease.
  3. Significant OA in the lateral compartment of the study knee, defined as Kellgren-Lawrence grade of > 2 as assessed by the investigator using X-ray.
  4. Significant OA in the patello-femoral compartment of the study knee, defined as Kellgren-Lawrence grade > 3 as assessed by the investigator using X-ray.
  5. Contralateral knee has radiographic evidence of OA (KL grade>2) AND clinical findings of OA symptoms that interfere with activities of daily living or require the use of an assist device
  6. Previous joint modifying surgery in the target knee within 12 months prior to planned surgery date such as ligament reconstruction or meniscus repair, cartilage transplantation, and microfracture

    a) Arthroscopic surgeries for joint lavage, meniscectomy, chondral debridement, and loose body removal are excluded if within 3 months prior to planned surgery date

  7. Previous lateral meniscectomy >30% of the target knee
  8. Previous patellar surgery in the target knee
  9. Previous osteotomy or failed knee joint replacement in the target knee
  10. Tibial-femoral valgus alignment >0⁰ as measured using mechanical axis on a long standing AP view x-ray
  11. Tibial-femoral varus alignment >7⁰ as measured using mechanical axis on a long standing AP view X-ray
  12. Hyperextension >5⁰
  13. Flexion deformity greater than 10⁰
  14. Ligamentous laxity, or meniscal instability as assessed by the investigator
  15. Cruciate ligament instability with Lachman test, grade 2 or higher
  16. Uncontrolled diabetes mellitus
  17. Current smoker or stopped \<1 year prior to enrollment
  18. Known or suspected diagnosis of Osteoporosis
  19. Paget's Disease of the bone
  20. Other metabolic disorders that may impair bone formation (must specify in records)
  21. Concomitant therapy
  22. Known or suspected diagnosis of Osteomalacia
  23. Known or suspected diagnosis of Osteonecrosis
  24. Infections which may spread to the implant site from distant foci
  25. Rapid joint destruction, marked bone loss or bone resorption apparent on x-ray
  26. Vascular insufficiency, muscular atrophy, neuromuscular disease
  27. Any significant medical condition (e.g., cancer, , chronic pain management for conditions such as neuropathic pain and fibromyalgia, significant psychiatric or neurological disorders, active alcohol/drug abuse, etc) or other factor (e.g. planned relocation, uncooperative patient) that the Investigator feels would interfere with study participation/completion
  28. Pregnancy or lactation or planning to become pregnant
  29. History of litigation for workers benefits for musculoskeletal injuries
  30. Currently enrolled in another clinical investigation that may influence the follow-up or may confound the outcome of this study
  31. Prisoners
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Phantom System

    Patients will be treated with the Phantom Knee System device

    Device: Phantom System

Interventions

  • DevicePhantom System

    Unloading of medial knee compartment with Phantom System

    Also known as: Phantom Knee System

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant Improvement in WOMAC Pain

    The number of participants with clinically significant improvement in WOMAC pain of at least 20% and ≥10 points from baseline to 24 months. WOMAC pain derived from the KOOS questionnaire.

    Time frame: Baseline and 24 months

  2. Number of Participants With Clinically Significant Improvement in WOMAC Function

    The number of participants with clinically significant improvement in WOMAC function of at least 20% and ≥10 points from baseline to 24 months. WOMAC function derived from the KOOS questionnaire.

    Time frame: Baseline and 24 months

07

Results

Posted Nov 18, 2026

Participant flow

40 subjects (30 in Poland and 10 in South Africa, N=14 in Phase 1 (Phantom FIH) and N=26 in Phase 2 (Phantom High Flex)

Participant flow — Overall Study
MilestonePhantom First in Human (FIH)Phantom High Flex
Started1426
Completed1426
Not completed00

Outcome measures

PrimaryNumber of Participants With Clinically Significant Improvement in WOMAC Pain

The number of participants with clinically significant improvement in WOMAC pain of at least 20% and ≥10 points from baseline to 24 months. WOMAC pain derived from the KOOS questionnaire.

Time frame:
Baseline and 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Improvement in WOMAC Pain
ParticipantsPhantom First in Human (FIH)Phantom High Flex
Number of Participants With Clinically Significant Improvement in WOMAC Pain1025
PrimaryNumber of Participants With Clinically Significant Improvement in WOMAC Function

The number of participants with clinically significant improvement in WOMAC function of at least 20% and ≥10 points from baseline to 24 months. WOMAC function derived from the KOOS questionnaire.

Time frame:
Baseline and 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Improvement in WOMAC Function
ParticipantsPhantom First in Human (FIH)Phantom High Flex
Number of Participants With Clinically Significant Improvement in WOMAC Function1024

Adverse events

Collected over Adverse Events collected from enrollment through 24 month visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phantom First in Human (FIH)0/14 (0%)4/14 (28.6%)4/14 (28.6%)
Phantom High Flex0/26 (0%)5/26 (19.2%)7/26 (26.9%)
Most frequent serious events
Most frequent serious events
EventPhantom First in Human (FIH)Phantom High Flex
Related - Mechanical failure - femoral ball dislocationSurgical and medical procedures3/140/26
Related - Knee painMusculoskeletal and connective tissue disorders1/142/26
Related - Mechanical failure of device or componentsSurgical and medical procedures1/140/26
Unrelated - Other: OA PainMusculoskeletal and connective tissue disorders1/140/26
Unrelated - Myocardial InfarctionCardiac disorders1/140/26
Unrelated - Knee PainMusculoskeletal and connective tissue disorders0/141/26
Unrelated - PneumoniaRespiratory, thoracic and mediastinal disorders0/141/26
Unrelated - Other: Bleeding from uteral myomasReproductive system and breast disorders0/141/26
Most frequent other events
Most frequent other events
EventPhantom First in Human (FIH)Phantom High Flex
Related - Knee painMusculoskeletal and connective tissue disorders1/143/26
Related - Audible clicking, squeaking, or other noise associated with deviceProduct Issues0/142/26
Related - Bone lossMusculoskeletal and connective tissue disorders0/142/26
Related - ROM insufficient or limitedMusculoskeletal and connective tissue disorders1/142/26
Related - Inflammation - OtherMusculoskeletal and connective tissue disorders1/140/26
Unrelated - Other: Contralateral Knee PainMusculoskeletal and connective tissue disorders1/140/26

Baseline characteristics

Enrolled Population

Age, Continuous
Age, Continuous(years)Phantom First in Human (FIH)Phantom High FlexTotal
Mean50.5 ± 9.550.9 ± 8.850.8 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Phantom First in Human (FIH)Phantom High FlexTotal
Female51015
Male91625
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phantom First in Human (FIH)Phantom High FlexTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White132538
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Phantom First in Human (FIH)Phantom High FlexTotal
South Africa4610
Poland102030
BMI
BMI((kg/m^2))Phantom First in Human (FIH)Phantom High FlexTotal
Mean28.0 ± 4.228.4 ± 3.228.3 ± 3.5
08

Study locations

4 sites
  • Zagiel Med Hospital
    Lublin, Poland
  • Carolina Medical Center
    Warsaw, Poland
  • Lekmed Medical Center
    Warsaw, Poland
  • Sports Science Institute of South Africa
    Cape Town, South Africa
09

References and documents

Publications

  • Slynarski K, Walawski J, Smigielski R, van der Merwe W. Two-Year Results of the PHANTOM High Flex Trial: A Single-Arm Study on the Atlas Unicompartmental Knee System Load Absorber in Patients With Medial Compartment Osteoarthritis of the Knee. Clin Med Insights Arthritis Musculoskelet Disord. 2019 Sep 23;12:1179544119877170. doi: 10.1177/1179544119877170. eCollection 2019. PubMed 31579106 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Nov 2017, 37 months.

Results were first posted in Nov 2026, 9 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2016
First posted
Mar 17, 2016
StartActual
Oct 2014
Primary completionActual
Nov 14, 2017
CompletionActual
Mar 2, 2018
Results first posted
Nov 18, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Withheld→Terminated Adequate data has been collected
changed Nov 18, 2026
Results
Results posted
posted Nov 18, 2026
Sites
4 sites added — first sites in Poland and South Africa
Show 4 added (3 Poland, 1 South Africa)
  • Zagiel Med Hospital · Lublin, Poland
  • Carolina Medical Center · Warsaw, Poland
  • Lekmed Medical Center · Warsaw, Poland
  • Sports Science Institute of South Africa · Cape Town, South Africa
Nov 18, 2026
Start date
Set to Oct 2014 (actual)
Nov 18, 2026
Primary completion
Set to Nov 14, 2017 (actual)
Nov 18, 2026
Study completion
Set to Mar 2, 2018 (actual)
Nov 18, 2026
Eligibility
Revised
Nov 18, 2026
Interventions
Arms or interventions changed
Nov 18, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 31579106 ↗
Nov 18, 2026
Title
[Trial of device that is not approved or cleared by the U.S. FDA]→Phantom Knee System Clinical Trial
Nov 18, 2026
Sponsor
[Redacted]→Moximed
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Withheld→Terminated
    Why stopped Adequate data has been collected
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 31579106 ↗
    4 sites added — first sites in Poland and South Africa
    Show 4 added (3 Poland, 1 South Africa)
    • Zagiel Med Hospital · Lublin, Poland
    • Carolina Medical Center · Warsaw, Poland
    • Lekmed Medical Center · Warsaw, Poland
    • Sports Science Institute of South Africa · Cape Town, South Africa
    Start date Set to Oct 2014 (now actual)
    Primary completion Set to Nov 14, 2017 (now actual)
    Study completion Set to Mar 2, 2018 (now actual)
    Eligibility Revised
    Interventions Arms or interventions changed
    Sponsor [Redacted]→Moximed
    Title [Trial of device that is not approved or cleared by the U.S. FDA]→Phantom Knee System Clinical Trial
    + 9 other changes: index terms, registry dates, verification date, oversight details, description, conditions, design details, secondary outcomes and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02711254
Lead sponsor
Moximed
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
Oct 2014
Primary completion
Nov 14, 2017
Completion
Mar 2, 2018
Results posted
Nov 18, 2026
Last update
Nov 18, 2026

Study contacts

Konrad Slynarski, MD
principal investigator · Lekmed Medical Center

Oversight

Data monitoring committee
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion